WO2008011072A3 - Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof - Google Patents

Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof Download PDF

Info

Publication number
WO2008011072A3
WO2008011072A3 PCT/US2007/016311 US2007016311W WO2008011072A3 WO 2008011072 A3 WO2008011072 A3 WO 2008011072A3 US 2007016311 W US2007016311 W US 2007016311W WO 2008011072 A3 WO2008011072 A3 WO 2008011072A3
Authority
WO
WIPO (PCT)
Prior art keywords
analogs
derivatives
androgen receptor
receptor modulators
selective androgen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/016311
Other languages
French (fr)
Other versions
WO2008011072A2 (en
Inventor
James T Dalton
Duane D Miller
Igor Rakov
Casey Bohl
Michael L Mohler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tennessee Research Foundation
Ohio State University Research Foundation
Original Assignee
University of Tennessee Research Foundation
Ohio State University Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2007275736A priority Critical patent/AU2007275736A1/en
Priority to JP2009520821A priority patent/JP2009543871A/en
Priority to MX2009000715A priority patent/MX2009000715A/en
Priority to BRPI0713198-4A priority patent/BRPI0713198A2/en
Priority to EP07836135A priority patent/EP2041077A2/en
Priority to EA200900202A priority patent/EA200900202A1/en
Application filed by University of Tennessee Research Foundation, Ohio State University Research Foundation filed Critical University of Tennessee Research Foundation
Priority to CA002658096A priority patent/CA2658096A1/en
Publication of WO2008011072A2 publication Critical patent/WO2008011072A2/en
Publication of WO2008011072A3 publication Critical patent/WO2008011072A3/en
Priority to IL196533A priority patent/IL196533A0/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C07C255/60—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton at least one of the singly-bound nitrogen atoms being acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/04—Derivatives of thiourea
    • C07C335/16—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C335/18—Derivatives of thiourea having nitrogen atoms of thiourea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

This invention provides new compounds and uses thereof in treating a variety of diseases or conditions in a subject, including, inter alia, prostate cancer, muscle wasting diseases and/or disorders or a bone-related diseases and/or disorders.
PCT/US2007/016311 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof Ceased WO2008011072A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2009520821A JP2009543871A (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
MX2009000715A MX2009000715A (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof.
BRPI0713198-4A BRPI0713198A2 (en) 2006-07-19 2007-07-19 selective modulators of androgen receptors, their analogs and derivatives, and their uses
EP07836135A EP2041077A2 (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
EA200900202A EA200900202A1 (en) 2006-07-19 2007-07-19 SELECTIVE ANDROGEN RECEPTOR MODULATORS, THEIR ANALOGUES AND DERIVATIVES AND THEIR USE
AU2007275736A AU2007275736A1 (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
CA002658096A CA2658096A1 (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
IL196533A IL196533A0 (en) 2006-07-19 2009-01-15 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US83188006P 2006-07-19 2006-07-19
US83198806P 2006-07-19 2006-07-19
US60/831,880 2006-07-19
US60/831,988 2006-07-19

Publications (2)

Publication Number Publication Date
WO2008011072A2 WO2008011072A2 (en) 2008-01-24
WO2008011072A3 true WO2008011072A3 (en) 2008-06-05

Family

ID=38957352

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2007/016312 Ceased WO2008011073A2 (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof
PCT/US2007/016311 Ceased WO2008011072A2 (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016312 Ceased WO2008011073A2 (en) 2006-07-19 2007-07-19 Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof

Country Status (12)

Country Link
US (2) US20090156614A1 (en)
EP (2) EP2041077A2 (en)
JP (2) JP2009543871A (en)
KR (2) KR20090030345A (en)
AR (1) AR063208A1 (en)
AU (2) AU2007275737A1 (en)
BR (2) BRPI0713200A2 (en)
CA (2) CA2658096A1 (en)
EA (2) EA200900202A1 (en)
IL (2) IL196533A0 (en)
MX (2) MX2009000714A (en)
WO (2) WO2008011073A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
EA201500845A1 (en) * 2005-11-28 2016-04-29 Джи Ти Икс, ИНК. AGENTS CONNECTING WITH NUCLEAR RECEPTORS
US7632838B2 (en) 2006-02-07 2009-12-15 Wyeth 11-beta HSD1 inhibitors
WO2008013791A2 (en) * 2006-07-24 2008-01-31 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
AU2008284662B2 (en) * 2007-08-07 2013-07-25 Takeda Pharmaceutical Company Limited Pyrrolidin-2 -one derivatives as androgen receptor modulator
AU2008296136A1 (en) 2007-09-07 2009-03-12 Bionovo. Inc. Estrogenic extracts of Scuttelaria barbata D. Don of the Labiatae Family and uses thereof
EP2222323A4 (en) 2007-11-19 2012-07-25 Bionovo Inc A process of making purified extract of scutellaria barbata d. don
US8268872B2 (en) 2008-02-22 2012-09-18 Radius Health, Inc. Selective androgen receptor modulators
MX2010009162A (en) 2008-02-22 2010-12-21 Radius Health Inc Selective androgen receptor modulators.
US20110105608A1 (en) * 2008-03-21 2011-05-05 Northeastern University Modulators of nuclear receptor co-regulatory protein binding
ITBO20090078A1 (en) * 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche COMPOUNDS FOR TREATING TUMOR TO THE PROSTATE AND PROCEDURES FOR THEIR SYNTHESIS
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
ITBO20090235A1 (en) * 2009-04-10 2010-10-11 Consiglio Nazionale Ricerche COMPOUNDS FOR TREATING TUMOR TO THE PROSTATE AND PROCEDURES FOR THEIR SYNTHESIS
EP2424853B1 (en) 2009-04-10 2018-09-19 Istituto Scientifico Romagnolo Per Lo Studio E La Cura Dei Tumori (I.R.S.T.) S.R.L. Non-steroidal compounds for androgen receptor modulation, processes for the preparation and uses thereof
US8450374B2 (en) * 2009-06-29 2013-05-28 University Of Delaware Pan-antagonists for the androgen receptor and androgen receptor mutants associated with anti-androgen withdrawal
US8277459B2 (en) 2009-09-25 2012-10-02 Tarsus Medical Inc. Methods and devices for treating a structural bone and joint deformity
AU2011203832A1 (en) * 2010-01-11 2012-08-23 Gtx, Inc. Methods of treating Meibomian gland dysfunction
GB201000685D0 (en) * 2010-01-15 2010-03-03 Glaxo Group Ltd Novel compounds
US8652141B2 (en) 2010-01-21 2014-02-18 Tarsus Medical Inc. Methods and devices for treating hallux valgus
CA2788907A1 (en) 2010-02-04 2011-08-11 Radius Health, Inc. Selective androgen receptor modulators
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
PT2568806T (en) 2010-05-12 2016-08-05 Radius Health Inc Therapeutic regimens
US8642632B2 (en) 2010-07-02 2014-02-04 Radius Health, Inc. Selective androgen receptor modulators
FI20105806A0 (en) 2010-07-15 2010-07-15 Medeia Therapeutics Ltd New arylamide derivatives with antiandrogenic properties
ES2550319T3 (en) 2010-09-28 2015-11-06 Radius Health, Inc Selective androgen receptor modulators
AR089703A1 (en) 2012-01-13 2014-09-10 Medeia Therapeutics Ltd ARILAMIDE DERIVATIVES THAT HAVE ANTIANDROGENIC PROPERTIES
JP6234376B2 (en) 2012-01-13 2017-11-22 アランダ ファーマ リミテッド Novel heteroarylamide derivatives with antiandrogenic properties
TW201332949A (en) 2012-01-13 2013-08-16 Medeia Therapeutics Ltd Novel arylamide derivatives having antiandrogenic properties
SI2844637T1 (en) 2012-05-02 2018-07-31 Boehringer Ingelheim International Gmbh Substituted 3-haloaliline SSAO inhibitors and their use
WO2014037811A2 (en) 2012-09-07 2014-03-13 The Governors Of The University Of Alberta Methods and compositions for diagnosis of inflammatory liver disease
US20140274979A1 (en) * 2013-03-13 2014-09-18 Golden Biotechnology Corporation Method for the treatment of fatty liver disease
WO2015102996A1 (en) * 2013-12-31 2015-07-09 Grasso Frank J Extremely high loading dose
RS67458B1 (en) 2014-03-28 2025-12-31 Univ Duke Treatment of an estrogen receptor positive breast cancer using a selective estrogen receptor modulator
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
KR101597327B1 (en) * 2014-04-24 2016-02-24 동아에스티 주식회사 Oxazolidine-based compound and selective androgen receptor agonists comprising the same
JOP20180072A1 (en) * 2014-09-11 2019-01-30 Lilly Co Eli Treatment of androgen deprivation therapy associated symptoms
US10441570B2 (en) 2015-04-21 2019-10-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) Ligands and methods of use thereof
US10865184B2 (en) 2015-04-21 2020-12-15 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10093613B2 (en) 2015-04-21 2018-10-09 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US9834507B2 (en) 2015-04-21 2017-12-05 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10017471B2 (en) 2015-04-21 2018-07-10 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10035763B2 (en) 2015-04-21 2018-07-31 Gtx, Inc. Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
KR20170138536A (en) 2015-04-21 2017-12-15 지티엑스, 인코포레이티드 Selective androgen receptor dissociation (SARD) ligands and methods for their use
JP6786520B2 (en) 2015-04-21 2020-11-18 ジーティーエックス・インコーポレイテッド Selective androgen receptor degradation agent (SARD) ligand and how to use it
US10806720B2 (en) 2015-04-21 2020-10-20 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
US11230523B2 (en) 2016-06-10 2022-01-25 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
RS63311B1 (en) 2016-06-22 2022-07-29 Ellipses Pharma Ltd AR+ METHODS OF BREAST CANCER TREATMENT
US11167007B2 (en) 2016-08-04 2021-11-09 City Of Hope FOXM1 modulators and uses thereof
KR102881465B1 (en) 2017-01-05 2025-11-04 래디어스 파마슈티컬스, 인코포레이티드 Polymorphic forms of rad1901-2hcl
WO2019025153A1 (en) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft USE OF SUBSTITUTED N-SULFONYL-N'-ARYLDIAMINOALKANES AND N-SULFONYL-N'-HETEROARYL DIAMINOALKANES OR THEIR SALTS TO INCREASE STRESSTOLERANCE IN PLANTS
WO2019084365A1 (en) * 2017-10-27 2019-05-02 St. Jude Children's Research Hospital, Inc. Methods and formulations for treatment of spinobulbar muscular atrophy
US12331027B2 (en) 2017-11-23 2025-06-17 Basf Se Herbicidal pyridylethers
BR112020008084B1 (en) 2017-11-23 2023-11-14 Basf Se PHENYL ETHERS, HERBICIDAL COMPOSITION, PROCESS FOR PREPARING ACTIVE COMPOSITIONS, METHOD FOR CONTROLLING UNWANTED VEGETATION AND USE OF PHENYL ETHERS
KR102054399B1 (en) 2018-03-26 2019-12-10 주식회사 프로텍바이오 Novel compound and pharmaceutical composition for preventing or treating obesity or metabolic syndrome comprising thereof
CN112423844B (en) 2018-07-04 2024-08-13 雷迪厄斯制药公司 Polymorphic forms of RAD1901-2HCL
WO2020051344A1 (en) 2018-09-05 2020-03-12 University Of Tennessee Research Foundation Selective androgen receptor degrader (sard) ligands and methods of use thereof
JOP20210218A1 (en) 2019-02-12 2023-01-30 Radius Pharmaceuticals Inc operations and vehicles
CN117751099A (en) * 2021-08-05 2024-03-22 中国药科大学 Amide compound and application thereof
CN121843920A (en) * 2023-08-28 2026-04-10 中国药科大学 Compounds as androgen receptor antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995284B2 (en) * 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2684965A (en) * 1950-08-10 1954-07-27 Abbott Lab Aminoalkylpiperidines
GB798410A (en) 1956-01-18 1958-07-23 Bofors Ab N-alkyl-tetrahydroquinaldinic acid amides
ITMI20012060A1 (en) 2001-10-05 2003-04-05 Recordati Chem Pharm NEW N-ACYLATED HETEROCYCLES

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995284B2 (en) * 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators

Also Published As

Publication number Publication date
JP2009543871A (en) 2009-12-10
BRPI0713198A2 (en) 2012-10-16
WO2008011073A2 (en) 2008-01-24
CA2658096A1 (en) 2008-01-24
MX2009000714A (en) 2009-07-27
AU2007275737A1 (en) 2008-01-24
BRPI0713200A2 (en) 2012-04-10
IL196534A0 (en) 2009-11-18
US20110077221A1 (en) 2011-03-31
MX2009000715A (en) 2009-07-22
WO2008011072A2 (en) 2008-01-24
KR20090035707A (en) 2009-04-10
KR20090030345A (en) 2009-03-24
US8110562B2 (en) 2012-02-07
AR063208A1 (en) 2009-01-14
EA200900203A1 (en) 2009-06-30
EP2040709A2 (en) 2009-04-01
IL196533A0 (en) 2009-11-18
EA200900202A1 (en) 2009-06-30
CA2658098A1 (en) 2008-01-24
WO2008011073A3 (en) 2008-10-23
EP2041077A2 (en) 2009-04-01
AU2007275736A1 (en) 2008-01-24
JP2009543872A (en) 2009-12-10
US20090156614A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
MX2009000715A (en) Selective androgen receptor modulators, analogs and derivatives thereof and uses thereof.
MX2009000385A (en) Substituted acylanilides and methods of use thereof.
WO2005120483A3 (en) Selective androgen receptor modulators and methods of use thereof
WO2008024456A3 (en) Substituted acylanilides and methods of use thereof
WO2008030367A3 (en) Selective myostatin inhibitors
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
WO2007126765A3 (en) Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
WO2007018797A8 (en) Selective nerve stimulation for the treatment of eating disorders
WO2007133802A3 (en) Pharmaceutical formulations of pimavanserin
LT2229369T (en) 6,7-dialkoxy-quinazoline derivatives useful for treatment of cancer-related disorders
IL178648A0 (en) Substituted morpholine compounds for the treatment of central nervous system disorders
PL2238110T3 (en) 5.6-bisaryl-2-pyridine-carboxamide derivatives, preparation thereof and therapeutic application thereof as antagonists for urotensine ii receptors
SI1729753T1 (en) Use of an nmda receptor antagonist for the treatment of tinnitus induced by cochlear excitotoxicity
SI2024368T1 (en) 6,7,8,9-tetrahydro-5h-pyrimidoš4,5-dćazepin-4-ylć-amine derivatives as modulators of trpv1 for the treatment of pain
EP2224919A4 (en) Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
IL172043A0 (en) Treating bone-related disorders with selective androgen receptor modulators
EP2192905A4 (en) Method for the selective therapy of disease
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
IL194833A0 (en) Polymorph forms of (2s)-(4e)-n-methyl-5-(3-isopropoxypyridin) yl]-4 penten-2-amine for the treatment of central nervous system disorders
WO2007118151A3 (en) Spirocyclic heterocyclic derivatives and methods of their use
WO2008087329A3 (en) New drug for treating gastric cancer
WO2008103431A3 (en) Dnai - liposomes
IL196615A0 (en) N-phenyl-prenylamine derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
IL196617A0 (en) Phenyl-prenyl-ether derivatives for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
SI2382013T1 (en) Selective histamine h4 receptor antagonists for the treatment of vestibular disorders.

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780034701.5

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007836135

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07836135

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007275736

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2658096

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009520821

Country of ref document: JP

Ref document number: MX/A/2009/000715

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007275736

Country of ref document: AU

Date of ref document: 20070719

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 542/KOLNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 1020097003234

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200900202

Country of ref document: EA

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 11564

Country of ref document: GE

ENP Entry into the national phase

Ref document number: PI0713198

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090119